Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Polypeptide >  Tesamorelin

Tesamorelin

Basic information Safety Supplier Related

Tesamorelin Basic information

Product Name:
Tesamorelin
Synonyms:
  • D06655
  • Tesamorelin (usan)
  • TesamorelinAcetate
  • Hot selling Pharmaceutical peptides 2mg Tesamorelin 99%
  • Tesamorelin (usan) USP/EP/BP
  • TIANFUCHEM--218949-48-5---Tesamorelin (usan)
  • Adipotide/FTTP
  • tesamorel
CAS:
218949-48-5
MF:
C221H366N72O67S
MW:
5135.86
EINECS:
603-809-2
Product Categories:
  • 218949-48-5
  • API
Mol File:
Mol File
More
Less

Tesamorelin Chemical Properties

storage temp. 
2-8°C Refrigerator
More
Less

Tesamorelin Usage And Synthesis

Description

Tesamorelin (usan) consists of the 44 amino acid sequence of human growth hormone releasing factor (GRF), with a 3-hexenoyl group attached to its tyrosine N-terminal residue. It is a new growth hormone releasing factor analogue, which can not only restore normal growth hormone secretion in the body, but also reduce the increased visceral adipose tissue (VAT), improve blood lipid abnormalities and quality of life, and maintain glucose homeostasis in the body.

Uses

Tesamorelin (usan) is indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy and is not recommended for weight loss.

Definition

FDA Pharm Classes: Tesamorelin is a Growth Hormone Releasing Factor Analog. The physiologic effect of tesamorelin is by means of Increased GHRH Activity.

Mechanism of action

Tesamorelin is a human growth hormone-releasing factor (GRF) analogue that works by regulating lipid metabolism, possibly by acting on pituitary cells in the brain to stimulate the production and release of the endogenous hormones hGRF and growth hormone, which in turn stimulate the production of insulin-like growth factor-1 (IGF-1), thereby decreasing the amount of body fat.

Side effects

Common adverse reactions of Tesamorelin (usan) include allergic reactions caused by growth hormone effects (such as arthralgia, peripheral edema, hyperglycemia), such as rash and urticaria, and erythema, itching, pain, urticaria and bleeding at the injection site.

Toxicology

In clinical trials in patients with HIV-associated lipodystrophy, tesamorelin therapy was not associated with de novo elevations in serum enzymes and, in some studies, was associated with decreases in preexisting ALT elevations, possibly mediated by improvements in nonalcoholic fatty liver. Instances of clinically apparent liver injury attributable to tesamorelin use have not been reported.

TesamorelinSupplier

YantaiBio Gold
Tel
13758194781 15083780366
Email
wudegui@tanzhenbio.com
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd Gold
Tel
+86-13393959797 +86-13393959797
Email
master@tsurgex.com
Wuhan Xinyan Biotechnology Co., Ltd. Gold
Tel
027-17764015852 17764015852
Email
xinyanbioch@gmail.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Cellmano Biotech Limited
Tel
0551-65326643 18156095617
Email
info@cellmano.com